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S. Salloway et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 9 (2017) 25-3426Abstract Introduction: Performance of the amyloid tracer [18F]flutemetamol was evaluated against three
pathology standard of truth (SoT) measures including neuritic plaques (CERAD “original” and
“modified” and the amyloid component of the 2012 NIA-AA guidelines).
Methods: After [18F]flutemetamol imaging, 106 end-of-life patients who died underwent postmortem
brain examination for amyloid plaque load. Blinded positron emission tomography scan interpretations
by five independent electronically trained readers were compared with pathology measures.
Results: By SoT, sensitivity and specificity of majority image interpretations were, respectively,
91.9% and 87.5% with “original CERAD,” 90.8% and 90.0% with “modified CERAD,” and
85.7% and 100% with the 2012 NIA-AA criteria.
Discussion: The high accuracy of either CERAD criteria suggests that [18F]flutemetamol predomi-
nantly reflects neuritic amyloid plaque density. However, the use of CERAD criteria as the SoT can
result in some false-positive results because of the presence of diffuse plaques, which are accounted
for when the positron emission tomography read is compared with the 2012 NIA-AA criteria.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Diagnostic; Sensitivity; Specificity; Alzheimer’s disease; Amyloid PET; Autopsy; [18F]Flutemetamol; Thalphasing1. Introduction
The presence of brain amyloid-beta (Ab) plaques is one of
several pathologic hallmarks of Alzheimer’s disease (AD)
[1]. Historically, Ab deposits could only be detected by his-
topathologic analysis of brain tissue obtained by brain biopsy
or at autopsy, using Ab antibodies [2] or histochemical dyes
with high affinity for fibrillar structure of Ab [3], and these
methods remain the standard of truth (SoT) for clinical
studies. The development of positron emission tomography
(PET) imaging agents, which detect fibrillar Ab in vivo
[4–10], has improved in-life diagnostic accuracy. Three
PET amyloid imaging agents (Neuraceq [florbetaben
[11,12], Piramal], Amyvid [florbetapir [12,13], Eli Lilly],
and Vizamyl [flutemetamol [14,15], GE Healthcare]) are
approved in the USA, Europe, and Japan. In all these
pivotal phase 3 studies image read performance of the
tracer compared with measurement of neuritic amyloid (via
Bielschowsky silver stain) was the SoT. [18F]florbetapir
reported 59 brains analyzed with a sensitivity and
specificity of 92% and 100%, respectively [5]. A total of 74
autopsy cases were available for [18F]florbetaben where
Sabri et al. [16] reported the samemetrics to be 98%and89%.
[18F]Flutemetamol was previously shown to selectively
target amyloid in vivo with high specificity [7,17]. Curtis
et al. [9] reported that blinded visual interpretations of
[18F]flutemetamol PET images in 68 end-of-life patients
had high sensitivity and specificity for estimating neuritic
plaque density.
This study expands the Curtis et al. study. Since that
study’s termination, 38 additional autopsy brains became
available from that PET imaged cohort. New guidelines
for the neuropathologic evaluation of AD were also released
[18] and include Thal phasing [19,20] based on
measurements of total (neuritic plus diffuse) Ab plaqueload. The Curtis et al. data contained two false-positive
images suspected to be related to diffuse Ab plaques. These
data were reanalyzed including the additional 38 brains, and
Thal phasing was used to help establish the cause of the
apparent false-positive scans. To test the robustness of the
SoT, variations in the neuritic amyloid plaque component
of the Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) criteria used in the Curtis et al. study
were also explored. This included validation against the
“original” CERAD (oCERAD) and “modified” CERAD
(mCERAD) criteria as described in Table 1. In contrast to
the methodology based on the CERAD criteria initially
described by Mirra et al. [21], which use a single measure-
ment in each assessed region, multiple samples per cortical
region were obtained, with the aim of reducing regional het-
erogeneity, providing a better estimate of regional burden for
comparison to PET imaging results. Finally, an electronic
reader training program including image reading methodol-
ogy and a testing module became available [22], obviating
the in-person reader training used in the Curtis study [9].2. Methods
2.1. Ethics
This study was conducted in accordance with the Decla-
ration of Helsinki, theGood Clinical Practice: Consolidated
Guideline approved by the International Conference on Har-
monisation, and applicable national and local laws and reg-
ulations. The initial study imaged the 180-subject cohort and
examined the first 68 brains [9] under institutional review
board (IRB) and ethics committee approval, and all patients
from whom samples would be analyzed in this study were
deceased, the IRBs granted exemption from IRB review
for this expanded autopsy collection. The investigators
Table 1
Summary of beta-amyloid standards of truth (SoT)
SoT priority in this study Primary SoT Secondary SoTs
SoT name
Modified CERAD
(mCERAD)
Original CERAD
(oCERAD)
2012 NIA-AA for
Thal phasing* Thal phasing*
Description of SoT Additional regions sampled
compared with oCERAD;
final score is the mean
CERAD 1991 regionsy;
final score is the modez
Additional regions sampled compared with oCERAD; final
score is the mean
Sampling (intraregional
numericy assessments,
averaged regions)
30! 8 30! 4 19 19
Regions MFL, MTG, STG, IPL,
ACG, PCG, PRC, PVC
MFL, MTG, STG, IPL MO, pons, MBr, CbCx, Dt, Th, STh, BG, Hi, EC, ACC, Amg,
MFG, MTG, STG, IPL, OC (BA 17 and 18), WM
Staining BSS BSS 4G8 IHC
Case dichotomy: definition
of “abnormal Ab plaque
count” (type of measure)
.1.5 (Quantitative) Moderate and frequent
(ordinal)z
Thal phase3 ANDmoderate
and frequent oCERAD
when
Thal phase 5 2
(quantitative)
N/A
Measure Sensitivity/specificity Sensitivity/specificity Sensitivity/specificity % of majority PET
results in each
Thal phase
Reference Curtis et al. [9] New SoT adapted from
Mirra et al. [21]
Hyman et al. [18]; Thal et al.
[19,20]
Thal et al. [19,20]
Rationale Representative of the mean
accumulation of neuritic
plaques in the eight areas
examined. EMA and FDA
recommendation as
primary SoT for product
approval
Representative of the
accumulation of neuritic
plaques in the totality
of the four areas examined,
because of multiple
assessments
Representative of the mean
accumulation of total
(neuritic and diffuse)
amyloid across multiple
regions
Representative of the
degree of accumulation
of total (neuritic and
diffuse) amyloid across
multiple regions
Abbreviations: ACC, anterior cingulate cortex; ACG, anterior cingulate gyrus; Amg, amygdala; BA, Broadmann area; BG, basal ganglia; BSS, Bielschowsky
silver stain; CbCx, cerebellar cortex; Dt, dorsal terminal nucleus; EC, entorhinal cortex; EMA, European Medicines Agency; FDA, Food and Drug Adminis-
tration; Hi, hippocampus; IHC, immunohistochemistry; IPL, inferior parietal lobe; MBr, midbrain; MFG, middle frontal gyrus; MFL, middle frontal lobe; MO,
medial orbital cortex; MTG, middle temporal gyrus; OC, occipital cortex; PCG, posterior cingulate gyrus; PET, positron emission tomography; PRC, precom-
missural nucleus; PVC, paraventricular cortex; STG, superior temporal gyrus; STh, subthalamic nucleus; Th, thalamus; WM, white matter.
*Thal phasing is used in a dichotomized format in Hyman et al. [18] to provide a measure of image accuracy, as opposed to a measure of amyloid burden.
yCERAD 1991: earliest CERAD criteria described by Mirra et al. [21], where the level of neuritic plaque burden is evaluated by one global BSS stain assess-
ment from the region of highest amyloid pathology. In contrast, in oCERAD for this work multiple samples (30 per region) were taken to reduce potential het-
erogeneity of pathology.
zMode is taken to allow a noncontinuous dichotomization of the amyloid load.
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consent unnecessary.2.2. Participants
A total of 180 terminally ill subjects with a life expectancy
of1 year, aged more than 55 years, and deemed able to un-
dergo study procedures were scanned between June 22, 2010
and November 23, 2011 as described in Curtis et al. [9]. Be-
tween July 2010 and February 2014, 108 subjects came to au-
topsy and 106 brains (68 of which previously reported by
Curtis et al. [9]) were considered of sufficient tissue quality
for histopathologic assessment. A single patient lacked image
interpretation data, which were therefore imputed.
Table 2 displays subject baseline demographics and char-
acteristics. Seventy-eight subjects (73.6%) had a history of
dementia and 50% had a clinical diagnosis of dementia
because of AD. [18F]Flutemetamol PET imaging was per-formed at a mean of 7.5 months (ranging between 0 and
28 months) before death. Safety data concerning the admin-
istration of Flutemetamol (18F) Injection were reported pre-
viously [9] (Clinicaltrials.gov: NCT02090855).2.3. [18F]Flutemetamol PET scanning
Patients underwent head computed tomography or mag-
netic resonance scanning either up to 6 months before the
PET scan or during PET imaging. The administered activity
of Flutemetamol (18F) Injection (Vizamyl, GE Healthcare,
Marlborough, MA, USA) was 185 to 370 MBq. PET acqui-
sition was carried out for 10 to 20 min (depending on the in-
jected activity) in 2-minute frames starting 90 minutes after
injection. Images were corrected for attenuation. Axial sli-
ces (128! 128) were generated by iterative reconstruction
and smoothed with a Gaussian postreconstruction filter
when required [9,23].
Table 2
Patient demographics and clinical characteristics
Variable All subjects (N 5 106)
Age* (y)
Mean (SD) 80.8 (8.87)
Median 83.0
Min, max 59, 95
Gender, n (%)
Male 48 (45.3)
Female 58 (54.7)
Race, n (%)
American Indian or Alaska Native 0 (0.0)
Asian 0 (0.0)
Black 4 (3.8)
Native Hawaiian or other Pacific Islander 0 (0.0)
Caucasian 99 (93.4)
Other 3 (2.8)
Ethnicity, n (%)
Hispanic or Latino 27 (25.5)
Not Hispanic or Latino 79 (74.5)
Time from PET scan to deathy (mo)
n 106
Mean (SD) 7.53 (6.948)
Median 5.45
Min, max 0.0, 28.2
Time from PET scan to death category, n (%)
1 y 82 (77.4)
.1 to 2 y 19 (17.9)
.2 to 3 y 5 (4.7)
History of dementiaz
Yes 87 (82.1)
No 19 (17.9)
Clinical diagnosisx, n (%)
Alzheimer’s disease 53 (50.0)
Other dementing disorderk 25 (23.6)
Mild cognitive impairment 0 (0.0)
No history of cognitive impairment 27 (25.5)
Memory loss (unspecified) 1 (0.9)
Abbreviations: PET, positron emission tomography;SD, standard deviation.
*Age was calculated as (date of informed consent2 date of birth)/365.25
rounded down to the nearest integer.
yTime from PET scan to death was calculated as (date of death2 date of
PET scan)/30.
zHistory of dementia was determined based on medical history reported
either at a trial site or by autopsy staff.
xClinical diagnosis was determined based on reported medical history.
kMay also have been an unspecified form of dementia.
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Blinded image evaluations (BIEs) of the [18F]flutemeta-
mol PET images were performed at a central review center
by five nuclear medicine physicians or radiologists (referred
to as “readers”) trained in the interpretation of [18F]fluteme-
tamol scans using the validated electronic training program
[22] and not involved in previous studies. Because the initial
blind had been broken to analyze the data for the initial 68
brain autopsy analysis [9], images were rerandomized and re-
read in a blinded fashion. The study used a dichotomized read,
requiring readers to classify images in a Sokoloff color scale
anchored to pons, as either normal or abnormal but not as un-
evaluable. Readers were allowed to use anatomic brain im-
ages (primarily computed tomography and more rarelymagnetic resonance imaging) to support interpretation at their
discretion. The regions read were frontal lobe, lateral tempo-
ral lobe, parietal lobe, posterior cingulate/precuneus, and
striatum. If any one of these regions was classified as positive
(i.e., abnormal for the presence of amyloid), then the whole
image was scored as positive. All readers were instructed to
examine the same five regions for amyloid positivity and to
report the read outcome both as a global measure and by
the individual regions. Further [18F]flutemetamol image
read methodology details can be found in Buckley et al. [22].2.5. Autopsy tissue histopathologic SoT measures
Brains were collected at 19 dementia clinics, memory cen-
ters, and hospice centers in the UK and USA. Postmortem
routine histopathologywas performed locallywithin 48 hours
of collectionon5mmthick paraffin sections after pretreatment
with 88% (vol/vol) formic acid for 5 minutes and heat-
mediated antigen retrieval [9]. Amyloid SoT measurements
were carried out at a central pathology laboratory for several
brain regions, twoblocks for each brain region and three slides
per block. Using a two-headed microscope, two blinded neu-
ropathologists evaluated simultaneously five randomly cho-
sen 2.5 mm2 fields of view per slide until a consensus on the
neuritic plaque count was reached. The average regional
scores were determined by averaging slide scores, which in
turn were determined by averaging the field of view scores.
The SoTs used are described further in Table 1. The SoT
used for the primary analysis was described as mCERAD
and involvedBielschowsky silver staining of amyloid plaques
in eight regions (the four original CERAD regions, plus ante-
rior and posterior cingulate, precuneus, and primary visual
cortex) [21,24]. mCERAD scores reflect the numerical
value associated with neuritic plaque burden: scores none
(0) and sparse (1) were interpreted as normal, whereas
moderate (2) and frequent (3) scores were interpreted as
abnormal. The cutoff score for abnormal plaque burden was
set as 1.5. A more detailed description of the pathology
methods and the neuropathologic analysis of the 106
individual autopsy cases are presented in Ikonomovic et al.
[23]. In particular, cerebral amyloid angiopathy (CAA) was
measured and categorized byVonsattel grade, stage, and type.
As a secondary SoT, the oCERAD method [21] involved
Bielschowsky silver staining assessment of neuritic plaques
from four neocortical regions (mid-frontal, superior and
middle temporal, and inferior parietal). The major difference
in this current methodology compared with that described in
Mirra et al. [21] was the expanded tissue sampling in each
region to reduce focal heterogeneity (Table 1). In addition,
age and dementia status, components used in the CERAD
diagnosis of AD by Mirra et al., were not used, as calcula-
tions of sensitivity and specificity simply relied on a compar-
ison of PET image read results with neuritic plaque scores.
Third, the 2012National Institute ofAgeing -Alzheimer’s
Association (NIA-AA) criteria with amyloid (Thal) phasing
involving total amyloid staining (monoclonal antibody, clone
S. Salloway et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 9 (2017) 25-34 294G8; SIG-39220, Covance, USA, diluted 1:100) were used.
The total amyloid staining pattern guided Thal phasing (a
0–5 scale according to the degree of regional spread of amy-
loid pathology, where a score3 indicates an abnormal load,
Fig. 1) [19]. A summary of each of these SoTs, collection
methods, and rationale for use and measures are described
in Table 1.
2.6. Data analysis
Each blinded visual image interpretation was compared
with the SoT measures outlined in Table 1 and classified
as a true-positive, false-positive, true-negative, or false-
negative (FN), and the classification counts were used to
calculate sensitivity and specificity. Intrareader reproduc-
ibility (IRR) was determined by including duplicate images
of a random sample (11 of 108,w10%) of the subjects’ im-
ages, combined randomly and reread along with the other
images. Inter-reader agreement (IRA) was determined as
described in Curtis et al. [9]. A subset analysis on subjects
who died within 1 year of PET imaging was also performed.
In addition, results were analyzed by time from PET scan to
death to determine whether there was an increase in the FN
rate over time (e.g., if patients with true negative scans later
developed abnormal amyloid levels). Finally, the proportion
of scans associated with each Thal phase as described in the
amyloid component of the 2012 NIA-AA criteria of Thal
phasing was determined [18,20].
2.7. Statistical analysis
The efficacy population analyzed comprised all subjects
who met the study entry criteria and had usable PET images.
Sensitivity and specificity were determined as point esti-
mates with exact two-sided 95% confidence intervals
(CIs). IRA and IRR were reported as percentage agreementFig. 1. Percentage of normal/abnormal [18F]flutemetamol majority image
interpretations by Thal phase. Green bar: negative scan interpretation; red
bar: positive scan interpretation.and Cohen’s kappa coefficients, respectively. IRAwas addi-
tionally reported as Fleiss’ kappa. The agreement between
the three SoT measures was also determined by Fleiss’s
kappa, whereas pairwise agreement was determined by Co-
hen’s kappa. Sample size was determined by the number of
autopsied subjects. Estimates of the distribution of SoT-
positive and SoT-negative brains, derived from the initial
assessment of the data reported in Curtis et al. [9], were
used to formulate assumptions of “true” sensitivity and spec-
ificity to perform power calculations. The success threshold
for the study was set to.75% for sensitivity and .60% for
specificity with respect to the lower bound of the 95% exact
binomial CI based on majority image interpretations.
Missing image interpretations were imputed as abnormal
(positive) if the SoT was normal (negative) and vice versa.
The imputed results for missing image interpretations were
then used to calculate the majority image interpretation.
The impact of covariates (e.g., age, gender, race, dementia
history, flutemetamol dose, neuritic plaque density, and
time from PET to autopsy) on outcome measures was as-
sessed using a logistic regression model. The PET-to-death
time interval was also evaluated with subset analyses using
exact two-sided 95% CIs.3. Results
In total, 106 evaluable subjects (105 with BIE performed
and one imputed) were examined (Table 2). By majority
image interpretation, 72 subjects’ (67.9%) scans were
amyloid-positive and 34 subjects’ (32.1%) scans were
amyloid-negative. Most image interpretations (87%) were
performed without consulting anatomic images. The range
of use of anatomic images of the five readers varied from
12% to 20%.
3.1. Neuropathologic findings
Using the Bielschowsky silver staining scoring in the pri-
mary SoT (mCERAD) regions, 76 subjects (71.7%) were
Ab-positive and the remaining 30 (28.3%) were Ab-nega-
tive. The distribution of neuritic plaque density represented
the full spectrum of amyloid neuritic plaque frequencies
with cases of none (17%), sparse (20%), moderate (32%),
and frequent (36%) plaque densities all being present in
this cohort of 106 brains (Fig. 2 and [23]). In addition, the
combined findings from the neuropathologic assessments
are presented in Supplementary Table 1.
3.2. [18F]Flutemetamol image interpretation: sensitivity
and specificity
Sensitivity and specificity are shown in Table 3. On the ba-
sis of the primary SoT (mCERAD), the majority image inter-
pretation had a sensitivity of 90.8% (FN rate of 9.2%) and
specificity was 90.0% (false-positive rate of 10.0%, or 7%
if the single imputed case was excluded) and the study met
its primary objective. Using oCERAD gave similar results
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AA criteria with Thal phasing as SoT, the specificity
increased to 100% (thus eliminating false-positive reads),
whereas the sensitivity slightly decreased to 85.7% (Table 3).
3.3. Relation between [18F]flutemetamol image
interpretation and Thal amyloid phasing
The percentages of normal/abnormal majority PET image
interpretations based on Thal phases are shown in Fig. 1. The
likelihood of an abnormal BIE increased with increased Thal
phase. An abnormal PET scan predicted late Thal phase
(4 or 5) with 90% probability (data not shown), whereas
there was 0% probability of an early Thal phase (0, 1, or
2). Conversely, a normal scan was associated with a 65%
probability of an early Thal phase (2 or less), but a 15%
chance of a late Thal phase (4 or 5, data not shown).
3.4. Impact of PET-to-death time interval
Subset analyses probed if the time between PET imaging
and death (up to 2.4 years) would increase the risk of FN re-
sults (i.e., PET-negative, pathology-positive). In patients
who died within 1 year after the PET scan, by-reader sensi-
tivity was 85.7% to 96.4% (majority value 89.3%) and by-
reader specificity was 80.8% to 92.3% (majority value
88.5%). In patients who died 1 to 2.4 years after the PET
scan, sensitivity and specificity were both .93.3%, indi-
cating that time to death did not influence tracer performanceFig. 2. Distribution of the selected population for the mean neuritic plaque sco
*5 False-positive read. mCERADSOT5 neuritic plaque density CERAD scoring
confidence. Reproduced with permission from Ikonomovic et al. [23].over this time period. A logistic regression analysis
confirmed these results, showing that PET-to-death time in-
terval was not significantly associated with an FN image
interpretation (P 5 .1751).
3.5. IRA, IRR, and SoT agreement
Pairwise IRA was .91.5%, with Cohen’s kappa ranging
from 0.80 to 0.92. Agreement across all five readers was
84.9%, with a Fleiss’ kappa of 0.84. IRR was 100.0%,
with a kappa of 1 for each reader. Agreement across the three
SoTs was 89.6%with a Fleiss’ kappa of 0.82. Cohen’s kappa
showed good agreement between the mCERAD and the
NIA-AA 2012 criteria (0.80) and between the oCERAD
and the NIA-AA 2012 criteria (0.75), whereas there was
an excellent agreement between mCERAD and oCERAD.4. Discussion
This study comprises a 106-subject autopsy cohort, which
represents the largest cohort to date aiming to assess accu-
racy in amyloid PET image reading [5,16,25,26]. Blinded
visual interpretation of [18F]flutemetamol images exhibited
high sensitivity and specificity (majority values of 90.8%
and 90.0%, respectively) using the mCERAD SoT. Similar
diagnostic performance was obtained using the secondary
SoTs (oCERAD and 2012 NIA-AA criteria, as per
Table 1). By reader (including the majority read), the three
95% CIs overlapped considerably for both sensitivity andre across the spectrum of amyloid pathology. ; 5 False-negative read.
(0–3). Note: several cases had borderline pathology, leading to lower reader
Table 3
Sensitivity and specificity of blinded visual interpretation of flutemetamol images according to three SoTs
Reader
Sensitivity,* % (95% CI) Specificity,y % (95% CI)
mCERAD oCERAD 2012 NIA-AAThal phasing mCERAD oCERAD 2012 NIA-AAThal phasing
1 96.1 (88.9, 99.2)z 95.9 (88.6, 99.2) 91.7 (83.6, 96.6) 83.3 (65.3, 94.4)x 78.1 (60.0, 90.7) 95.5 (77.2, 99.9)
2 89.5 (80.3, 95.3)z 90.5 (81.5, 96.1) 84.5 (75.0, 91.5) 90.0 (73.5, 97.9)x 87.5 (71.0, 96.5) 100.0 (84.6, 100.0)
3 88.2 (78.7, 94.4)z 87.8 (78.2, 94.3) 82.1 (72.3, 89.6) 93.3 (77.9, 99.2)x 87.5 (71.0, 96.5) 100.0 (84.6, 100.0)
4 88.2 (78.7, 94.4)z 89.2 (79.8, 95.2) 84.5 (75.0, 91.5) 83.3 (65.3, 94.4)x 81.3 (63.6, 92.8) 95.5 (77.2, 99.9)
5 94.7 (87.1, 98.5)z 95.9 (88.6, 99.2) 90.5 (82.1, 95.8) 86.7 (69.3, 96.2)x 84.4 (67.2, 94.7) 100.0 (84.6, 100.0)
Majorityk 90.8 (81.9, 96.2)z 91.9 (83.2, 97.0) 85.7 (76.4, 92.4) 90.0 (73.5, 97.9)x 87.5 (71.0, 96.5) 100.0 (84.6, 100.0)
Abbreviations: CI, confidence interval; SoT, standard of truth.
*Primary analysis. Sensitivity 5 true positives/(true positives 1 false negatives).
ySpecificity 5 true negatives/(true negatives 1 false positives).
zTwo-sided 95% CI with a lower bound .75%.
xTwo-sided 95% CI with a lower bound .60%.
kThe majority interpretation is the interpretation made independently by more than half of the readers.
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SoTs. These results compare favorably to those reported pre-
viously by Curtis et al. [9]. In this study, however, because of
the larger number of subjects, the 95% CIs were narrower,
reflecting increased precision around the measurements. A
strong regional association between the tracer andmCERAD
and oCERAD regions has also been reported [21], see Table 6
of Ikonomovic et al. [23] and a good correspondence
between quantitative measures of fibrillar amyloid and
[18F]flutemetamol PET signal from normal pressure hydro-
cephalus patients who had cortical biopsy sampling either
before or after PET imaging [27].
When dichotomized Thal phasing according to 2012
NIA-AA criteria [18] was used as the SoT, the specificity
was raised to 100%. This SoT combines the presence of
both neuritic and diffuse Ab-immunoreactive plaques (i.e.,
total Ab plaque burden), and these new results suggest that
[18F]flutemetamol detects both forms of Ab plaques when
present in sufficient amounts. These observations with the
Thal-based SoT are thought to explain the three apparent
false-positive cases observed when neuritic plaque density
alone was used as the SoT. The approximate 90% accuracy
of [18F]flutemetamol performancewhen neuritic plaque den-
sity alone is the SoT suggests that in this cohort of 106 sub-
jects most of the detected amyloid was present as neuritic
plaques; the rise to 100% specificity indicates a small num-
ber of cases contributing to the visual PET signal when both
neuritic and diffuse plaques are present and detected. These
observations are expected to be similarly applicable to quan-
titative PET image read, as strong concordance with visual
read results has been demonstrated previously [28].
This study (data in Fig. 1) also confirms the previous find-
ings [19] that visual interpretation of [18F]flutemetamol PET
images strongly predicts Thal phase, which reflects the pro-
gressive deposition of brain amyloid from neocortex (phase
1), to allocortex (phase 2), to diencephalon and basal ganglia
(phase 3), to midbrain and medulla oblongata (phase 4), and
finally to cerebellum and pons (phase 5). [18F]Flutemetamol
is particularly effective in detecting the most advanced Thal
phases (4 and 5) [19] where the deposition of amyloid wasrecorded in clinically proven AD cases in the original
work by Thal et al. [20]. Similarly, in this work, a positive
scan interpretation was best predicted by an increasing
spread of amyloid burden, whereas a low burden restricted
to neocortex and allocortex (Thal phases 0–2) was always
associated with a negative scan. Conversely, a negative
(normal) scan was associated with a 65% probability of an
early Thal phase (0, 1, or 2), but only a 15% chance of a
late Thal phase (4 or 5). These results confirm that the likeli-
hood of a positive scan interpretation increases with the pro-
gressive deposition of amyloid. There were five cases, which
were Thal phase 4 but were reviewed as normal by majority
visual PET read (Fig. 1) and Fig. 6c of Ikonomovic et al.
[29]. In these cases, atrophy played a significant part in di-
minishing the gray matter intensity in the PET images lead-
ing to a majority normal (FN) assessment. The majority
reads for these cases were mostly not unanimous.
The results of the [18F]flutemetamol-related Thal analysis
are complementary to those of Murray et al. [30] who used
the research tracer [11C]PiB to compare autopsy findings
with PET image results. Murray et al. report a boundary be-
tween Thal phases 1 and 2 equating to a [11C]PiB threshold of
.1.4whereas [18F]flutemetamol reports positivity coming in
at Thal phase 3. These differences may be because of the use
of quantitation for the [11C]PiBmeasure, which is likely to be
more sensitive than the visual inspection methods used
currently for the routine use of fluorine-18 labeled tracers.
Additional insight into the diagnostic value of
[18F]flutemetamol can be gathered by its striatal uptake
pattern [31]. [18F]Flutemetamol is unique across the fluori-
nated PET amyloid tracers, in that it uses the striatum as
one of its key read regions. The striatum contains amyloid pri-
marily in the diffuse form [28] and is less susceptible to atro-
phy than the neocortex [32], hence its value in scan
interpretation [22,31]. Increasing levels of striatal amyloid
were found to be associated with increasing sensitivity of
image interpretation, from 77% for moderate striatal plaque
density to 82% for frequent plaques [31]. These values of
sensitivity are lower than those observed with mCERAD
and oCERAD as SoTs (Table 3) suggesting that compared
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intense in diffuse plaques. Furtherwork is ongoing in this area
to better understand the relationship between different forms
of amyloid pathology and [18F]flutemetamol imaging signal.
For example, the useof plaquearea and signal intensity to give
an integrated density is being investigated by Ikonomovic
et al. [29], who showed that using the fluorescent labeled
probe cyano-flutemetamol neuritic plaques give a stronger
signal than diffuse plaques of similar area. This finding is
consistent with the lower sensitivity reported by Beach et al.
[31] when striatal pathology alone is used as the SoT.
Regarding specificity, the observations in this article are
consistent with the results of Beach et al. [31]; specificity
was 100% (i.e., no false-positive image interpretations) using
the 2012 NIA-AA criteria with Thal phasing, whether based
on the striatum alone or on the global brain regions analyzed.
Both articles contribute to understanding the nature of amy-
loid pathology in the brain and the limitations of using
neuritic Ab plaques as the SoT measurement for character-
izing the performance of PET amyloid imaging agents.
Within the 106 autopsy data set were seven FN cases
based on majority PET read. Three of these had borderline
neuritic plaque scores, and three of the remaining four had
some discordance between brain region plaque scoring and
the PET read. Hence, most of the FN cases may be explained
by the difficulty in assigning a positive or negative amyloid
score for borderline cases, coupled with the cortical atrophy
present in all FN cases. Six of the seven FN cases were not
unanimous in terms of the reported read results (four cases
of four negative/one positive; two cases of three negative/
two positive, data not shown). There was only one case
with extensive radial atrophy where all five readers unani-
mously interpreted the case as PET negative in the presence
of positive cortical amyloid (data not shown). These obser-
vations point to the importance of using an anatomic image
when atrophy is suspected [15,22].
In addition to neuritic and diffuse amyloid, the presence
of CAA could contribute to the PET signal. In this autopsy
cohort, there were no cases where CAA was present in the
absence of fibrillar amyloid, although there was circumstan-
tial evidence to suggest that when the cortical neuritic amy-
loid was borderline, the presence of CAA pathology may
have contributed to a majority positive PET read. More evi-
dence however is required, and studies to examine amyloid
imaging in intracerebral lobar hemorrhage, for example,
may give us clues as to the extent of CAA deposition and
how that compares to a PET amyloid signal.
In this study, sensitivity and specificity were unaffected
by time from PET scan to death, consistent with the research
by Villemagne et al. [33], that amyloid deposition occurs
over decades. IRA was higher than previously reported in
Curtis et al. [9] (.91.5%, k 5 0.80–0.92 compared with
80%, k 5 0.44–0.97), although one reader in Curtis
et al. [9] was clearly an outlier. The overall improvement
in IRA may be the result of training readers with a validated
electronic reader training program [22], which provides reli-able, dependable instruction, and skill development for ac-
curate PET image interpretation, even when a possibly
substantial number of subjects manifested severe cortical at-
rophy (a potential confounding factor for image interpreta-
tion [34]). As for the SoT agreement, although overall a
very good agreement between the three pathologic criteria
was found, the slightly lower concordance between the
mCERAD/oCERAD and NIA-AA 2012 would be expected
because mCERAD and oCERAD are based on Bielschow-
sky silver stain identifying neuritic amyloid alone whereas
NIA-AA 2012 is based on total fibrillar amyloid load.
The comparison between visual image reads and quanti-
tation of [18F]flutemetamol was the subject of a publication
by Thurfjell et al. [28]. Here a threshold between negative
and positive amyloid was derived based on a mean plus
two standard deviations in a healthy group. When applied
to a cohort of more than 170 subjects from a reader valida-
tion study [22], the concordance was .99% when using
either the pons or whole cerebellum as a reference region.
When quantitation was compared with the read results
from cases where there was a histology SoT there was
near identical sensitivity and specificity from both the visual
read and quantitative comparisons [28].
This study had several limitations. Our primary results
were the majority interpretation of five readers, a research
setting that does not reflect clinical practice. The study’s
end-of-life population does not reflect the patient demo-
graphic anticipated to benefit most from amyloid PET imag-
ing in the clinical setting (patients with mild cognitive
impairment), but was a necessary trade-off for comparing
PET image interpretations to autopsy findings. The high pro-
portion of Caucasian subjects could be viewed as a limitation
to this study; however, recent data indicate that [18F]fluteme-
tamol has similar performance in both Caucasian and Japa-
nese subjects and that readers interpret negative and positive
scans almost identically [35]. The Japanese study also used
visual interpretation of images, which may have involved
some degree of judgment for scans close to the pathology
thresholds and those with severe atrophy; theoretically,
these cases might benefit from quantitative measurement
of [18F]flutemetamol uptake [28] as described previously.
Nevertheless, experience in image reading has shown that
the inferior parietal area and the striatum are less susceptible
to atrophy than other regions. Thus, from a visual read
perspective, these areas provide a more robust region to
observe when atrophy is suspected [20].
In conclusion, this reported study found that in a cohort of
106 autopsy cases, the visual interpretation of [18F]fluteme-
tamol PET images had high sensitivity and specificity in de-
tecting brain amyloid in life, regardless of the SoT measure.
It also provides evidence that [18F]flutemetamol binds to
both neuritic and diffuse plaques, and that the striatum,
which is little affected by atrophy, is a robust region for
assessing brain amyloid. The newly found specificity of
[18F]flutemetamol for both neuritic and diffuse Ab plaques
(which possibly precedes neuritic plaque formation)
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dementia [36].
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1. Systematic review: The authors reviewed the literature
using traditional sources (e.g., PubMed), clinical study
reports, and internal reports. The sensitivity and spec-
ificity of the visual interpretation of [18F]flutemetamol
images following in-person training were previously
evaluated against an autopsy-based standard of truth,
albeit in a smaller cohort.
2. Interpretation: The findings presented here led to a
refined interpretation for apparently false-positive
[18F]flutemetamol image reads and to a more pre-
cise estimation of sensitivity and specificity.
3. Future directions: The additional benefit of quantita-
tive image processing could add value to results ob-
tained using visual assessment alone, particularly
when pathology is borderline between sparse and
moderate plaques.References
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